Results 141 to 150 of about 38,804 (267)

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B‐cell lymphoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 5, September 2026.
Abstract Few studies have evaluated the impact of organ‐specific tumor microenvironments (TMEs) on clinical outcomes in diffuse large B‐cell lymphoma (DLBCL). This study investigated potential molecular markers, the immune cell composition within the TME, and their associations with clinical outcomes in patients with primary intestinal DLBCL (PI‐DLBCL).
Wei‐Li Ma, Tsai‐Yun Chen, Pei‐An Fu, Jo‐Pai Chen, Ming Yao, Hsiu‐Po Wang, Been‐Ren Lin, Chung‐Wu Lin, Chia‐Lang Hsu, Chung‐Yu Huang, Ann‐Lii Cheng, Sung‐Hsin Kuo   +11 more
wiley   +1 more source

Extranodal lymphomas.

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013
CHIAPPELLA, Annalisa, BENEVOLO, Giulia, VITOLO, Umberto   +2 more
openaire   +2 more sources

Single‐Cell Profiling Identifies SLC2A5‐Mediated Fructose Metabolism as a Vulnerability in Primary CNS Lymphoma

Advanced Science, Volume 13, Issue 53, 24 September 2026.
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu, Qianru Zhang, Wenqiang Yan, Lu Sun, Yiran Cui, Bolin Liu, Guoqing Han, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Qingguo Li, Gang An, Yuxuan Liu   +13 more
wiley   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1496-1506, September 2026.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Hodgkin Reed–Sternberg‐Like Cells in T‐Cell/Histiocyte‐Rich Large B‐Cell Lymphoma

eJHaem, Volume 7, Issue 5, October 2026.
Ulysses Mustaki, Stephen Lade, Mary Ann Anderson, Kah Lok Chan   +3 more
wiley   +1 more source

Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B‐Cell Lymphoma With Bulky Disease

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Bulky disease represents a clinically aggressive subset of diffuse large B‐cell lymphoma (DLBCL) associated with adverse clinical outcomes. The aim of this study was to investigate the influence of oncogenic mutations and tumor microenvironment alterations on bulky disease in DLBCL.
Yu‐Qing Wang, Yue Wang, Zhi‐Shan Du, Xin‐Yun Huang, Yan Dong, Shuang Tian, Di Fu, Shu Cheng, Li Wang, Peng‐Peng Xu, Sheng‐Jin Fan, Shu‐Ye Wang   +11 more
wiley   +1 more source

Extranodal Lymphoproliferative Processes

, 2017
Zeppa P., Cozzolino I.
openaire   +2 more sources

Mediastinal Extranodal Follicular Dendritic Cell Sarcoma: A Case Report

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2014
Follicular dendritic cell sarcoma is a spindle cell neoplasm, originating from follicular dendritic cells. It frequently presents in lymph nodes. Occasionally, it occurs in extranodal regions like head and neck, mediastinum, gastrointestinal system.
Arbil Acikalin, Emine Kilic Bagir, Eif Calis, Ezgi Ozyilmaz, Melek Ergin, Derya Gumurdulu   +5 more
doaj